New Treatment For Eczema Receives FDA Clearence

More than 15 million Americans are diagnosed with atopic dermatitis, commonly referred to as eczema. The chronic inflammatory disease that affects 90 percent of patients within the first five years of their lives, is characterized by red, dry, itchy skin that rashes. This uncomfortable and unpleasant condition largely affects children but can also affect adults and often leads to sleep interruption due to the severity of the itch.
While many products to treat eczema are currently available, the FDA has recently cleared a new approach in managing the signs and symptoms of eczema called Mimyx cream. Unlike current prescription therapies, Mimyx is safe enough to be used on patients of any age and there is no limit on the duration of use.
The new therapy is currently available by prescription only. For more information on Mimyx cream, including complete prescribing information, contact Stiefel laboratories at 1-800-724-1565.